Guide AF: guiding anticoagulation decisions for atrial fibrillation in long-term care
Active Grant Awarded
- Award ID
- R01AG100018
- Recipient
-
Hebrew Rehabilitation Center UEI WS29EMGEVEJ4
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $670,774
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- Roslindale, MA 02131, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Hebrew Rehabilitation Center, doing business as Hebrew Senior Life, $670,774 on September 16, 2026, under Grant R01AG100018 in the Aging Research program (CFDA 93.866). The grant funds Guide AF, a study generating real-world evidence on the benefits and harms of continuing, discontinuing, or initiating oral anticoagulation (OAC) for older adults with atrial fibrillation (AF) at long-term care (LTC) admission, with the goal of supporting individualized care decisions.
The recipient will conduct pharmacoepidemiologic studies comparing continuing versus stopping OAC and initiating versus staying off OAC during transition to LTC, develop and validate models predicting individualized OAC effects among new LTC residents with AF, and develop, refine, and field test an OAC decision aid. The work uses the Long-Term Care Data Cooperative electronic health records linked to Medicare fee-for-service, Medicare Advantage, and Minimum Data Set assessments.
Place of performance is Roslindale, MA 02131, USA, and the ultimate completion date is May 31, 2031.
Description
- Abstract
- Oral anticoagulation (OAC) reduces the risk of ischemic stroke in patients with atrial fibrillation (AF) but also increases the risk of bleeding, especially as patients age and their health status declines. Therefore, OAC strategies require ongoing reassessment to account for changes in risk, benefit, and patient preferences. Among 8 million older adults in the U.S. With AF, approximately 1 in 4 patients transition to long-term care (LTC) during their remaining lifetime. This transition is a sentinel event-a critical change in a person's health, cognition, and function that necessitates a reassessment of the risks and benefits of OAC. For new LTC residents with AF, the median life expectancy is 1.5 years, and the disability burden is high. Yet, evidence to guide the decisions to continue, discontinue, or initiate OAC at the time of LTC admission remains limited. The objective of the proposed research is to generate real-world evidence on the benefits and harms of continuing, discontinuing, or initiating OAC LTC and to develop a decision aid to support individualized care. Leveraging the long-term care data cooperative electronic health records linked to medicare fee-for-service, medicare advantage, and minimum data set assessments, the study will: 1) conduct pharmacoepidemiologic studies to determine the benefits and harms of continuing VS. Stopping OAC and initiating VS. Staying off OAC when transitioning to LTC; 2) develop and validate models to predict individualized estimates of OAC effects among new LTC residents with AF; and 3) develop, refine, and field test an OAC decision aid. The proposal leverages a nationwide, linked database that integrates multiple real-world data sources, including electronic health records that provide rich clinical data unavailable in medicare data and minimum data set assessments. The decision aid will incorporate multiple rounds of input from residents, care partners, and clinicians to ensure the decision aid addresses the end-users' decisional needs. The decision aid developed from this research will be prepared for a future pilot randomized controlled trial, followed by a full-scale, efficacy randomized clinical trial in enhancing individualized informed decision-making.
Quick answers
Who received award R01AG100018?
R01AG100018 was awarded to Hebrew Rehabilitation Center by National Institute on Aging (National Institutes of Health) on September 16, 2026.
How much is award R01AG100018 worth?
$670,774 has been obligated on R01AG100018.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award